Nasdaq

Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB)

Positive SCID mouse data further support the preclinical safety and dosing profile of SON-1010 for oncology applications No evidence of cytokine storm was observed Company is on track to submit an IND ...
Nasdaq

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted ...
Seeking Alpha

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months ...